May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Inter-Country Differences in Patients’ Perception of Humanistic Burden of Neovascular Age-Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • A. J. Lotery
    Ophthalmology - Eye Unit, Southampton General Hospital, Southampton, United Kingdom
  • A. F. Cruess
    Dalhousie University, Halifax, Nova Scotia, Canada
  • X. Xu
    Covance Inc., Gaithersburg, Maryland
  • G. Zlateva
    Pfizer Inc, New York, New York
  • T. F. Goss
    Covance Inc., Gaithersburg, Maryland
  • T. Knight
    Covance Inc., Gaithersburg, Maryland
  • Footnotes
    Commercial Relationships A.J. Lotery, Pfizer Inc, C; Pfizer Inc, R; A.F. Cruess, Pfizer, C; Novartis, C; Pfizer, R; Novartis, R; X. Xu, Pfizer Inc, C; G. Zlateva, Pfizer, E; T.F. Goss, Pfizer Inc, C; T. Knight, Pfizer Inc, C.
  • Footnotes
    Support Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2111. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. J. Lotery, A. F. Cruess, X. Xu, G. Zlateva, T. F. Goss, T. Knight; Inter-Country Differences in Patients’ Perception of Humanistic Burden of Neovascular Age-Related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2007;48(13):2111.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Limited research has examined differences in patients’ perception of the burden of AMD across countries. A multi-country, cross-sectional study was conducted to examine by country the burden of bilateral subfoveal, neovascular AMD on patient-reported functioning.

Methods:: A total of 401 bilateral neovascular AMD patients from retina clinics and 471 elderly non-AMD (control) patients from general medical practices were surveyed in Canada, France, Germany, Spain, and the United Kingdom (UK). Physicians recorded demographic and clinical information. Patients completed a telephone survey of the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale (HADS), and health resource utilization. We evaluated the impact of AMD on patients’ QOL and functioning using multivariate regression models for each country.

Results:: The average ages of AMD patients were similar across countries (76.2-79.6), and the majority (63% -69%) were females. AMD patients consistently reported substantially worse NEI VFQ, HADS, and EQ-5D scale scores than the control subjects after adjusting for age, gender, and co-morbid diseases. However, substantial differences were also observed in AMD patients across countries. The French AMD patients reported the worst vision-related functioning (adjusted mean NEI VFQ overall scale score 12 points [21%] lower than the Spanish AMD patients who had the best functioning) and the most anxiety symptoms on the HADS anxiety scale (2.4 points [39%] higher [worse] than the UK AMD patients who had the least symptoms). German AMD patients reported the most depression symptoms on the HADS depression scale (4.3 points [74%] higher than the Canadian AMD patients who had the least symptoms), but the best general QOL on the EQ-5D (0.13 points [21%] higher than the French AMD patients who had the worst QOL]. Compared to the control group, French AMD patients reported the greatest decrement (57%) in vision-related functioning than in other countries, while German AMD patients reported the least decrements (40%).

Conclusions:: We observed a great variation in bilateral AMD patients’ perception of their QOL, vision-related functioning, and anxiety and depression symptoms across countries, even though within each country, AMD patients consistently reported substantially lower QOL than the control patients.

Clinical Trial:: TBD

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • quality of life 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×